<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells in vitro reproduces many of the activation effects of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> of primary B lymphocytes, <z:chebi fb="2" ids="33699">mRNAs</z:chebi> induced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells have been cloned and identified by subtractive hybridization </plain></SENT>
<SENT sid="1" pm="."><plain>Nine genes encode <z:chebi fb="40" ids="33697">RNAs</z:chebi> which are 4- to &gt; 100-fold more abundant after <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two of these, the genes for CD21 and vimentin, were previously known to be induced by <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Five others, the genes for cathepsin H, annexin VI (p68), serglycin <z:chebi fb="0" ids="37396">proteoglycan</z:chebi> core protein, CD44, and the myristylated alanine-rich protein kinase C substrate (MARCKS), are genes which were not previously known to be induced by <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Two novel genes, EBV-induced genes 1 and 2 (EBI 1 and EBI 2, respectively) can be predicted from their cDNA sequences to encode G protein-coupled <z:chebi fb="7" ids="16670">peptide</z:chebi> receptors </plain></SENT>
<SENT sid="5" pm="."><plain>EBI 1 is expressed exclusively in B- and T-lymphocyte cell lines and in lymphoid tissues and is highly homologous to the interleukin 8 receptors </plain></SENT>
<SENT sid="6" pm="."><plain>EBI 2 is most closely related to the thrombin receptor </plain></SENT>
<SENT sid="7" pm="."><plain>EBI 2 is expressed in B-lymphocyte cell lines and in lymphoid tissues but not in T-lymphocyte cell lines or peripheral blood T lymphocytes </plain></SENT>
<SENT sid="8" pm="."><plain>EBI 2 is also expressed at lower levels in a promyelocytic and a histiocytic cell line and in pulmonary tissue </plain></SENT>
<SENT sid="9" pm="."><plain>These predicted G protein-coupled <z:chebi fb="7" ids="16670">peptide</z:chebi> receptors are more likely to be mediators of EBV effects on B lymphocytes or of <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocyte functions than are genes previously known to be up-regulated by <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
</text></document>